CGN Advisors’s Pfizer PFE Stock Holding History

CGN Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,288	Closed	-$275K	–	257
2023 Q3	$275K	Sell	8,288 -566	-6%	-$20K	0.04%	226
2023 Q2	$325K	Buy	8,854 +192	+2%	+$7.47K	0.05%	189
2023 Q1	$353K	Sell	8,662 -465	-5%	-$20.1K	0.06%	181
2022 Q4	$468K	Buy	9,127 +474	+5%	+$22.7K	0.08%	169
2022 Q3	$379K	Buy	8,653 +1,540	+22%	+$74.8K	0.1%	182
2022 Q2	$373K	Buy	7,113 +55	+0.8%	+$2.8K	0.11%	169
2022 Q1	$365K	Buy	7,058 +13	+0.2%	+$675	0.09%	171
2021 Q4	$416K	Buy	+7,045	New	+$349K	0.11%	162

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

CGN Advisors's PFE Position: Q4 2023 in Review

CGN Advisors sold out of Pfizer (PFE) in Q4 2023, closing a stake of 8,288 shares — an estimated $275K sold.

CGN Advisors first reported a position in PFE in Q4 2021 and held it in 8 quarters. The position peaked at $468K in Q4 2022. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

CGN Advisors reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
CGN Advisors sold 8,288 Pfizer shares in Q4 2023, an estimated $275K.
CGN Advisors first reported a position in Pfizer in Q4 2021 and held it in 8 quarters.
CGN Advisors's Pfizer position peaked at $468K in Q4 2022.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on CGN Advisors's 13F filing for Q4 2023, filed 5 Jan 2024.